South Korea Approves Blood Cancer Test and Dementia Screen

South Korea's national health system took a major step Tuesday toward making advanced cancer monitoring and dementia screening available to its 50 million citizens.

The country's health technology evaluation body approved three medical tools for its insurance coverage pathway, including a tablet-based cognitive test for dementia and a blood test that tracks the genetic mutation behind the most common chronic blood cancers. Together, the approvals signal that precision medicine and digital health tools are moving from luxury to standard care.

The cancer test measures something doctors desperately need to know: how much of a patient's blood carries the JAK2 V617F mutation. This single DNA change drives more than 95 percent of polycythemia vera cases and up to 65 percent of two other chronic blood cancers.

What makes the approval remarkable is that the test uses a simple blood draw instead of a painful bone marrow biopsy. Patients can now get serial monitoring to catch disease progression early, track treatment response, and assess their risk for dangerous blood clots—all from routine bloodwork.

The cognitive screening tool, called the Seoul Cognitive Status Test, runs on a 12-inch Android tablet and takes patients through voice and touchscreen tasks. It's designed for clinics that don't have specialized neuropsychologists on staff, bringing dementia screening to primary care offices across the country.

Both tools target Korea's aging population. The country has one of the world's fastest-growing elderly demographics, making early dementia detection and cancer monitoring increasingly critical public health needs.

The Ripple Effect

South Korea's approval process matters far beyond its borders. The country operates a single-payer health system that covers 97 percent of its population, meaning government reimbursement decisions determine whether new medical tools actually reach patients.

When Korea's evaluation body clears a technology, it's applying the same rigorous evidence standards to diagnostics, devices, and digital platforms simultaneously. That unified framework offers a model for other universal healthcare systems wrestling with how to pay for precision medicine.

The designation as "new health technology" is the mandatory first gate before price negotiations with Korea's insurance system can begin. Now that both tools have cleared that hurdle, hospitals can pursue coverage and patients can access testing without crushing out-of-pocket costs.

For the blood cancer test, that means oncologists can monitor mutation levels over time to personalize treatment with drugs like ruxolitinib, the current frontline therapy. For the dementia screen, it means catching cognitive decline earlier when interventions have the greatest impact.

South Korea has built what many health systems aspire to: a pathway that can evaluate 21st-century medical innovation as quickly as it arrives, then make it available to essentially everyone.